Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1995 1
1996 1
2000 3
2001 2
2003 1
2011 1
2014 1
2015 1
2016 1
2017 1
2018 3
2019 4
2020 2
2021 4
2022 12
2023 6
2024 6
2025 4

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

47 results

Results by year

Filters applied: . Clear all
Page 1
Certolizumab pegol, abatacept, tocilizumab or active conventional treatment in early rheumatoid arthritis: 48-week clinical and radiographic results of the investigator-initiated randomised controlled NORD-STAR trial.
Østergaard M, van Vollenhoven RF, Rudin A, Hetland ML, Heiberg MS, Nordström DC, Nurmohamed MT, Gudbjornsson B, Ørnbjerg LM, Bøyesen P, Lend K, Hørslev-Petersen K, Uhlig T, Sokka T, Grondal G, Krabbe S, Lindqvist J, Gjertsson I, Glinatsi D, Kapetanovic MC, Aga AB, Faustini F, Parmanne P, Lorenzen T, Giovanni C, Back J, Hendricks O, Vedder D, Rannio T, Grenholm E, Ljoså MK, Brodin E, Lindegaard H, Söderbergh A, Rizk M, Kastbom A, Larsson P, Uhrenholt L, Just SA, Stevens DJ, Bay Laurbjerg T, Bakland G, Olsen IC, Haavardsholm EA, Lampa J; NORD-STAR study group. Østergaard M, et al. Ann Rheum Dis. 2023 Oct;82(10):1286-1295. doi: 10.1136/ard-2023-224116. Epub 2023 Jul 9. Ann Rheum Dis. 2023. PMID: 37423647 Free article. Clinical Trial.
Active conventional treatment and three different biological treatments in early rheumatoid arthritis: phase IV investigator initiated, randomised, observer blinded clinical trial.
Hetland ML, Haavardsholm EA, Rudin A, Nordström D, Nurmohamed M, Gudbjornsson B, Lampa J, Hørslev-Petersen K, Uhlig T, Grondal G, Østergaard M, Heiberg MS, Twisk J, Lend K, Krabbe S, Hyldstrup LH, Lindqvist J, Hultgård Ekwall AK, Grøn KL, Kapetanovic M, Faustini F, Tuompo R, Lorenzen T, Cagnotto G, Baecklund E, Hendricks O, Vedder D, Sokka-Isler T, Husmark T, Ljoså MA, Brodin E, Ellingsen T, Söderbergh A, Rizk M, Olsson ÅR, Larsson P, Uhrenholt L, Just SA, Stevens DJ, Laurberg TB, Bakland G, Olsen IC, van Vollenhoven R; NORD-STAR study group. Hetland ML, et al. BMJ. 2020 Dec 2;371:m4328. doi: 10.1136/bmj.m4328. BMJ. 2020. PMID: 33268527 Free PMC article. Clinical Trial.
Interstitial Lung Disease in Patients With Rheumatoid Arthritis or Psoriatic Arthritis Initiating Biologics and Controls: Data From 5 Nordic Registries.
Provan SA, Ljung L, Kristianslund EK, Michelsen B, Uhlig T, Jonmundsson T, Sexton J, Gudbjornsson B, Di Giuseppe D, Hetland ML, Reynisdottir GB, Glintborg B, Relas H, Aaltonen K, Kvien TK, Askling J. Provan SA, et al. Among authors: relas h. J Rheumatol. 2024 Nov 1;51(11):1111-1118. doi: 10.3899/jrheum.2024-0252. J Rheumatol. 2024. PMID: 39218450 Free article.
Effectiveness of secukinumab in radiographic and non-radiographic axial spondyloarthritis: a European routine-care observational study.
Christiansen SN, Horskjær Rasmussen S, Ostergaard M, Pons M, Michelsen B, Pavelka K, Codreanu C, Ciurea A, Glintborg B, Santos MJ, Sari I, Rotar Z, Gudbjornsson B, Macfarlane GJ, Relas H, Iannone F, Laas K, Wallman JK, van de Sande M, Provan SA, Castrejon I, Zavada J, Mogosan C, Nissen MJ, Loft AG, Barcelos A, Erez Y, Pirkmajer KP, Grondal G, Jones GT, Hokkanen AM, Chimenti MS, Vorobjov S, Di Giuseppe D, Kvien TK, Otero-Varela L, van der Horst-Bruinsma I, Hetland ML, Ørnbjerg LM. Christiansen SN, et al. Among authors: relas h. RMD Open. 2024 Jul 24;10(3):e004166. doi: 10.1136/rmdopen-2024-004166. RMD Open. 2024. PMID: 39053949 Free PMC article.
Disparities in the organisation of national healthcare systems for treatment of patients with psoriatic arthritis and axial spondyloarthritis across Europe.
Michelsen B, Østergaard M, Nissen MJ, Ciurea A, Möller B, Midtbøll Ørnbjerg L, Horák P, Glintborg B, MacDonald A, Laas K, Sokka-Isler T, Gudbjornsson B, Iannone F, Hellamand P, Kvien TK, Rodrigues AM, Codreanu C, Rotar Z, Castrejón I, Wallman JK, Pavelka K, Loft AG, Heddle M, Vorobjov S, Relas H, Gröndal G, Gremese E, van der Horst-Bruinsma I, Kristianslund EK, Santos MJ, Mogosan C, Tomsic M, Diaz-Gonzalez F, Giuseppe DD, Nielsen SW, Hetland ML. Michelsen B, et al. Among authors: relas h. Health Policy. 2025 Jun;156:105311. doi: 10.1016/j.healthpol.2025.105311. Epub 2025 Apr 4. Health Policy. 2025. PMID: 40245675 Free article. Review.
The relationship between lifestyle factors and outcome of treatment with TNFα inhibitors in axial spondyloarthritis - results from 14 European countries.
Jones GT, Rotariu O, MacDonald R, Michelsen B, Glintborg B, van der Horst-Bruinsma I, Gudbjornsson B, Geirsson AJ, Relas H, Isomäki P, Závada J, Pavelka K, Rotar Z, Tomšič M, Nissen MJ, Ciurea A, Codreanu C, Wallman JK, Kristianslund EK, Rasmussen SH, Ørnbjerg LM, Santos MJ, Østergaard M, Hetland ML, Macfarlane GJ. Jones GT, et al. Among authors: relas h. BMC Rheumatol. 2025 Jul 11;9(1):88. doi: 10.1186/s41927-025-00529-4. BMC Rheumatol. 2025. PMID: 40646655 Free PMC article.
The occurrence of multiple treatment switches in axial spondyloarthritis. Results from five Nordic rheumatology registries.
Di Giuseppe D, Lindström U, Aaltonen K, Relas H, Provan S, Gudbjornsson B, Hetland ML, Askling J, Kauppi M, Geirsson AJ, Chatzidionysiou K, Jørgensen TS, Dreyer L, Michelsen B, Jacobsson L, Glintborg B. Di Giuseppe D, et al. Among authors: relas h. Rheumatology (Oxford). 2022 Aug 30;61(9):3647-3656. doi: 10.1093/rheumatology/keab946. Rheumatology (Oxford). 2022. PMID: 34940795
European bio-naïve spondyloarthritis patients initiating TNF inhibitor: time trends in baseline characteristics, treatment retention and response.
Christiansen SN, Ørnbjerg LM, Rasmussen SH, Loft AG, Askling J, Iannone F, Zavada J, Michelsen B, Nissen M, Onen F, Santos MJ, Pombo-Suarez M, Relas H, Macfarlane GJ, Tomsic M, Codreanu C, Gudbjornsson B, Van der Horst-Bruinsma I, Di Giuseppe D, Glintborg B, Gremese E, Pavelka K, Kristianslund EK, Ciurea A, Akkoc N, Barcelos A, Sánchez-Piedra C, Peltomaa R, Jones GT, Rotar Z, Ionescu R, Grondal G, Van de Sande MGH, Laas K, Østergaard M, Hetland ML. Christiansen SN, et al. Among authors: relas h. Rheumatology (Oxford). 2022 Aug 30;61(9):3799-3807. doi: 10.1093/rheumatology/keab945. Rheumatology (Oxford). 2022. PMID: 34940840
One-Third of European Patients With Axial Spondyloarthritis Reach Pain Remission With Routine Care Tumor Necrosis Factor Inhibitor Treatment.
Ørnbjerg LM, Rugbjerg K, Georgiadis S, Rasmussen SH, Lindström U, Pavelka K, Yilmaz N, Favalli EG, Nissen MJ, Michelsen B, Vieira-Sousa E, Jones GT, Ionescu R, Relas H, Sanchez-Piedra C, Tomšič M, Geirsson AJ, van der Horst-Bruinsma I, Askling J, Loft AG, Nekvindova L, Direskeneli H, Iannone F, Ciurea A, Fagerli KM, Santos MJ, Macfarlane GJ, Codreanu C, Eklund K, Pombo-Suarez M, Rotar Z, Gudbjornsson B, Rusman T, Østergaard M, Hetland ML. Ørnbjerg LM, et al. Among authors: relas h. J Rheumatol. 2023 Aug;50(8):1009-1019. doi: 10.3899/jrheum.220459. Epub 2022 Dec 1. J Rheumatol. 2023. PMID: 36455943
47 results